An observational study in Systemic Vascular Resistance, sponsored by Parc de Salut Mar. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-03-05.
Sponsored by Parc de Salut Mar · Observational
Obese patients have increased cardiovascular risk and target organ damage (TOD) as compared to people with normal weight. Weight loss reduces cardiovascular risk and TOD. These changes have been associated mainly to changes in inflammatory and pro-atherogenic markers. Office peripheral blood pressure (BP) appears to decrease after bariatric surgery, but information on changes in 24h-ambulatory-BP-monitoring (24h-ABPM) and central-BP(cBP), or about the possible role of renin-angiotensin-aldosterone (RAAS), serotonin(STS) and endocannabinoid(ECS) systems is scarce. Our hypothesis is that the hemodynamic changes mediated by alterations in the RAAS, STS and ECS after weight loss are also responsible for the reduction of TOD.
Parc de Salut Mar is the lead sponsor of 180 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients aged 18 - 65 years, who have medical indication for treatment with bariatric surgery and agreeing to undergo the intervention.
Exclusion Criteria:
Mean changes 24h-aortic systolic-blood pressure (SBP) measured in mmHg
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean changes in aortic- 24h, daytime and nighttime blood pressure estimates others than 24h systolic blood pressure measured in mmHg
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean changes in peripheral- 24h, daytime and nighttime blood pressure estimates measured in mmHg
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in office blood pressure estimates measured in mmHg
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in arterial stiffness parameters (I)
pulse wave velocity measured in m/s
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in arterial stiffness parameters (II)
augmentation index measured in %
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in Left ventricular mass index
Left ventricular mass index measured in g/m2
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in Left atrium diameter
Left atrium diameter measured in mm
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in Ejection fraction
Ejection fraction measured in %,
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in left ventricular remodeling index
left ventricular remodeling index, do not have units
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in carotid intima-media thickness measured in mm
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in biochemical parameters measured in mg/dl or mmol/L
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in the components of the renin-angiotensin system
renin-angiotensin system: plasma renin activity: ng/mL/h, plasma aldosterone: pg/ml, angiotensinogen: mng/100ml, angiotensin 1-7: pg/ml, ACE: UI/l, ACE-2: UI/I
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in the serotonergic system components
serotonergic system: 5-HIAA:ng/ml, 5-HT:ng/mL
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in the components of the endocannabinoid system
endocannabinoid system: Anandamide: nmol/mL, 2-arachidonoylglycerol: mg/ml
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Mean change in pro-atherosclerotic markers
pro-atherosclerotic markers: omentine-1: ng/ml, chemerine: ng/ml, leptin: ng/ml, adiponectine: mcg/ml
Time frame: From baseline to the final exam (12 months) with intermediate evaluations at 1, 3 and 6 months.
Plan to share: No
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Parc de Salut Mar